# Study of Ambrisentan in Participants With Pulmonary Hypertension

> **NCT00777920** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 140 (actual)

## Conditions studied

- Pulmonary Hypertension

## Interventions

- **DRUG:** Ambrisentan

## Key facts

- **NCT ID:** NCT00777920
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11-17
- **Primary completion:** 2019-09-11
- **Final completion:** 2019-09-11
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2020-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00777920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00777920, "Study of Ambrisentan in Participants With Pulmonary Hypertension". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00777920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*